FDA Approves First-of-Its Kind Treatment for Type 1 Narcolepsy

Written by Ted Samson

Posted on August 26, 2026

Feel better informed on narcolepsy and get real support from your community.

The U.S. Food and Drug Administration (FDA) has approved a first-of-its-kind treatment for type 1 narcolepsy called oveporexton (Orzeyful). The drug is an oral orexin receptor 2 (OX2R)-selective agonist. It’s designed to improve how the body produces a chemical messenger that helps regulate wakefulness, sleep, and muscle tone.

In clinical trials, adults who took oveporexton showed improved ability to stay awake during the day, less daytime sleepiness, and fewer episodes of cataplexy (sudden, brief loss of voluntary muscle control and strength).

Researchers also observed improvements in other narcolepsy symptoms, including sleep paralysis, hallucinations, and disrupted nighttime sleep.

🗳️ How satisfied are you with your current narcolepsy treatment plan?

Very satisfied

Somewhat satisfied

Somewhat dissatisfied

Very dissatisfied

Additional findings showed that about 70 percent of people who took oveporexton reported no significant cognitive difficulties compared with about 15 percent of those who took a placebo (inactive treatment).

What Is Oveporexton?

Oveporexton is an OX2R-selective agonist. An agonist is a drug that activates a specific receptor.

Orexin is a chemical messenger that helps regulate wakefulness, sleep, and muscle tone. In type 1 narcolepsy, the brain loses orexin-producing cells. Oveporexton is thought to help by activating OX2R and restoring some of the wake-promoting signaling that’s missing.

Researchers also think OX2R activation may help stabilize sleep-wake transitions and reduce abnormal rapid eye movement (REM)-sleeplike symptoms, including cataplexy.

The drug is indicated for narcolepsy type 1 in adults. It’s taken as an oral tablet twice daily.

What Did the Phase 3 Studies Find?

Researchers evaluated oveporexton in two global, multicenter, placebo-controlled studies that included a total of 273 adults with type 1 narcolepsy. Participants were followed for 12 weeks.

Among study findings:

Oveporexton was associated with better daily functioning at week 12 than placebo across six areas, including everyday activities, everyday responsibilities, cognitive functioning, cataplexy, social activities, and tiredness.
About 70 percent of participants across the oveporexton group had no significant cognitive difficulties compared with about 15 percent in the placebo group.
Exploratory sleep findings suggested better nighttime sleep quality.
Most participants who received oveporexton reported no hallucinations or sleep paralysis.
Most participants who received the twice-daily dose also reported meaningful reductions in nighttime sleep disturbances.

Side Effects To Know About

As with all treatments, ovepotexton may cause side effects. The most common ones include insomnia, increased urinary frequency, urgency to urinate, and increased saliva production.

What Does This Approval Mean for People With Type 1 Narcolepsy?

Treatment for type 1 narcolepsy generally focuses on individual symptoms. Care may include medicines that promote wakefulness or stimulants for excessive daytime sleepiness, along with medicines that help reduce cataplexy or other symptoms. Lifestyle changes can also be part of the treatment picture.

This approval adds a new type of option: a medicine designed to restore orexin signaling and address a broad range of daytime and nighttime symptoms.

It may change how people and their healthcare providers talk about treatment. However, it doesn’t replace existing options for everyone or mean that everyone will respond in the same way.

If you have narcolepsy and your current treatment isn’t giving you the results you want, talk with your healthcare provider about what other options may be available.